ASCO: Moderate Activity Linked to Longer Survival in Advanced CRC

Share this content:
A half hour of moderate activity each day translated into a 16 percent decrease in the progression of CRC.
A half hour of moderate activity each day translated into a 16 percent decrease in the progression of CRC.

(HealthDay News) -- Just a half hour a day of moderate physical activity could improve survival odds for patients with metastatic colorectal cancer (CRC), according to a study presented at the American Society of Clinical Oncology's annual Gastrointestinal Cancers Symposium, held from Jan. 19 to 21 in San Francisco.

Study authors who tracked 1,231 CRC patients found a 19 percent decline in risk for early death among those who got 30 minutes or more of moderate exercise daily. Five or more hours of moderate -- but non-vigorous -- activity a week pushed that survival benefit to 25 percent. Walking, cleaning, or gardening counted as moderate exercise, the study authors said.

A half hour of such activity daily also translated into a 16 percent decrease in the progression of disease, the researchers found. The findings held up even after accounting for a range of factors, including patient age, body weight, overall health, other serious disease, or the particular type of cancer treatment underway. The researchers noted that advanced-stage CRC patients only appeared to derive benefit from moderate -- not vigorous -- activity. No similar link was seen with routinely engaging in more strenuous sports or running.

"While exercise is by no means a substitute for chemotherapy, patients can experience a wide range of benefits from as little as 30 minutes of exercise a day," lead author Brendan Guercio, M.D., a resident physician at Brigham and Women's Hospital in Boston, said in a symposium news release.

Press Release
More Information

Loading links....

Sign Up for Free e-newsletters

Regimen and Drug Listings

GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION

Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Genitourinary Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Rare Cancers Regimens
Skin Cancer Regimens Drugs